

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

HC 02120

3/5/74

Licensee

In accordance with the letter dated
March 31, 2006 (with attached close-out survey dated March 20, 2006), and facsimile received August 10, 2006,

1. Scheurer Hospital
2. 170 N. Caseville Road
Pigeon, MI 48755

3. License number 21-32250-01 is amended in its entirety to read as follows:

4. Expiration date August 31, 2010

5. Docket No. 21-30-35444
Reference No.

6. Byproduct, source, and/or special nuclear material

- A. Any byproduct material permitted by 10 CFR 35.100
- B. Any byproduct material permitted by 10 CFR 35.200
- C. Any byproduct material permitted by 10 CFR 35.300

7. Chemical and/or physical form

- A. Any
- B. Any
- C. Any (excluding I-131 for thyroid carcinoma therapy)

8. Maximum amount that licensee may possess at any one time under this license

- A. As needed
- B. As needed
- C. As needed (not to exceed one curie of iodine-131)

9. Authorized Use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300 (excluding I-131 for carcinoma therapy).

CONDITIONS

10. A. Licensed material shall be used at the licensee's facilities located at 170 N. Caseville Road, Pigeon, Michigan.
- B. Licensed material identified in Items 6.A. and 6.B. may be used at temporary job sites of medical care facilities anywhere in the United States where the U.S. Nuclear Regulatory Commission maintains jurisdiction for regulating the use of licensed material.

MATERIALS LICENSE SUPPLEMENTARY SHEET

License Number

21-32250-01

Docket or Reference Number

030-35444

Amendment No. 4

11. The Radiation Safety Officer for this license is Mark Guilfoyle, D.O.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users

Material and Use

Mark Guilfoyle, D.O.

10 CFR 35.100, 35.200 and 35.300
(excluding I-131 for thyroid carcinoma therapy).

David Carter, M.D.

10 CFR 35.100, 35.200 and 35.300
(excluding I-131 for thyroid carcinoma therapy).

Clare A. Scheuren, Jr. M.D.

10 CFR 35.100 and 35.200

Stanislaw Pniewski, M.D.

10 CFR 35.100 and 35.200

Jose A. Carrion, M.D.

10 CFR 35.100 and 35.200

Kaneez B. Shaikh, M.D.

10 CFR 35.100 and 35.200

H. Tansuche, M.D.

10 CFR 35.100 and 35.200

Herminio Calderon, M.D.

10 CFR 35.100, 35.200 and 35.300
(excluding I-131 for thyroid carcinoma therapy).

James J. Snider, M.D.

10 CFR 35.100, 35.200 and 35.300
(excluding I-131 for thyroid carcinoma therapy).

Frederick W. Coop, M.D.

10 CFR 35.100 and 35.200.

Peter J. Clive, M.D.

10 CFR 35.100 and 35.200.

John J. Ference, M.D.

10 CFR 35.100 and 35.200.

Leopold M. Fregoli, M.D.

10 CFR 35.100 and 35.200.

Daniel K. Shogren, D.O.

10 CFR 35.100 and 35.200.

David P. Tracy, M.D.

10 CFR 35.100 and 35.200.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number


21-32250-01

Docket or Reference Number

030-35444

Amendment No. 4

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated April 10, 2000; and,
- B. Letters dated August 30, 2000, October 16, 2000, December 1, 2005, and **March 31, 2006 (with attached close-out survey dated March 20, 2006); and,**
- C. Facsimile received **August 10, 2006.**



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date AUG 15 2006

By

William P. Reichhold
Materials Licensing Branch
Region III